Autologous mRNA-electroporated dendritic cell vaccine (Radboud University)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAutologous mRNA-electroporated dendritic cell vaccine (Radboud University)

Drug Alias NameN/A

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionTyrosinase modulatorsMelanocyte protein PMEL modulators

TargetsMelanocyte protein PMELTyrosinase

Therapy Area/IndicationsUveal melanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesRadboud University Nijmegen

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRadboud University Nijmegen

Active IndicationsN/A

Inactive IndicationsUveal melanoma

Other Information

ATC CodeN/A